129 related articles for article (PubMed ID: 37468364)
1. Serum cytokine profiles in patients with pancreatic cancer and chronic pancreatitis.
Lanki M; Mustonen H; Salmi M; Jalkanen S; Haglund C; Seppänen H
Pancreatology; 2023 Sep; 23(6):657-662. PubMed ID: 37468364
[TBL] [Abstract][Full Text] [Related]
2. Pancreatic cancer survival prediction via inflammatory serum markers.
Lanki M; Seppänen H; Mustonen H; Salmiheimo A; Stenman UH; Salmi M; Jalkanen S; Haglund C
Cancer Immunol Immunother; 2022 Sep; 71(9):2287-2292. PubMed ID: 35034144
[TBL] [Abstract][Full Text] [Related]
3. Serum cytokine biomarker panels for discriminating pancreatic cancer from benign pancreatic disease.
Shaw VE; Lane B; Jenkinson C; Cox T; Greenhalf W; Halloran CM; Tang J; Sutton R; Neoptolemos JP; Costello E
Mol Cancer; 2014 May; 13():114. PubMed ID: 24884871
[TBL] [Abstract][Full Text] [Related]
4. Independent Validation and Assay Standardization of Improved Metabolic Biomarker Signature to Differentiate Pancreatic Ductal Adenocarcinoma From Chronic Pancreatitis.
Mahajan UM; Oehrle B; Sirtl S; Alnatsha A; Goni E; Regel I; Beyer G; Vornhülz M; Vielhauer J; Chromik A; Bahra M; Klein F; Uhl W; Fahlbusch T; Distler M; Weitz J; Grützmann R; Pilarsky C; Weiss FU; Adam MG; Neoptolemos JP; Kalthoff H; Rad R; Christiansen N; Bethan B; Kamlage B; Lerch MM; Mayerle J
Gastroenterology; 2022 Nov; 163(5):1407-1422. PubMed ID: 35870514
[TBL] [Abstract][Full Text] [Related]
5. Distinct pathophysiological cytokine profiles for discrimination between autoimmune pancreatitis, chronic pancreatitis, and pancreatic ductal adenocarcinoma.
Ghassem-Zadeh S; Gaida MM; Szanyi S; Acha-Orbea H; Frossard JL; Hinz U; Hackert T; Strobel O; Felix K
J Transl Med; 2017 Jun; 15(1):126. PubMed ID: 28578701
[TBL] [Abstract][Full Text] [Related]
6. Blood small extracellular vesicles derived miRNAs to differentiate pancreatic ductal adenocarcinoma from chronic pancreatitis.
Guo S; Qin H; Liu K; Wang H; Bai S; Liu S; Shao Z; Zhang Y; Song B; Xu X; Shen J; Zeng P; Shi X; Chen H; Gao S; Xu J; Pan Y; Xiong L; Li F; Zhang D; Jiao X; Jin G
Clin Transl Med; 2021 Sep; 11(9):e520. PubMed ID: 34586739
[TBL] [Abstract][Full Text] [Related]
7. Growth differentiation factor (GDF-15) concentration combined with Ca125 levels in serum is superior to commonly used cancer biomarkers in differentiation of pancreatic mass.
Hogendorf P; Durczyński A; Skulimowski A; Kumor A; Poznańska G; Strzelczyk J
Cancer Biomark; 2018 Feb; 21(3):505-511. PubMed ID: 29171983
[TBL] [Abstract][Full Text] [Related]
8. Sequential Validation of Blood-Based Protein Biomarker Candidates for Early-Stage Pancreatic Cancer.
Capello M; Bantis LE; Scelo G; Zhao Y; Li P; Dhillon DS; Patel NJ; Kundnani DL; Wang H; Abbruzzese JL; Maitra A; Tempero MA; Brand R; Firpo MA; Mulvihill SJ; Katz MH; Brennan P; Feng Z; Taguchi A; Hanash SM
J Natl Cancer Inst; 2017 Apr; 109(4):. PubMed ID: 28376157
[TBL] [Abstract][Full Text] [Related]
9. Differentiation of pancreatic ductal adenocarcinoma from chronic pancreatitis by PAM4 immunohistochemistry.
Shi C; Merchant N; Newsome G; Goldenberg DM; Gold DV
Arch Pathol Lab Med; 2014 Feb; 138(2):220-8. PubMed ID: 24476519
[TBL] [Abstract][Full Text] [Related]
10. Metabolic biomarker signature to differentiate pancreatic ductal adenocarcinoma from chronic pancreatitis.
Mayerle J; Kalthoff H; Reszka R; Kamlage B; Peter E; Schniewind B; González Maldonado S; Pilarsky C; Heidecke CD; Schatz P; Distler M; Scheiber JA; Mahajan UM; Weiss FU; Grützmann R; Lerch MM
Gut; 2018 Jan; 67(1):128-137. PubMed ID: 28108468
[TBL] [Abstract][Full Text] [Related]
11. Serum tumor markers not useful in screening patients with pancreatic mucinous cystic lesions associated with malignant changes.
Pezzilli R; Calculli L; Melzi d'Eril G; Barassi A
Hepatobiliary Pancreat Dis Int; 2016 Oct; 15(5):553-557. PubMed ID: 27733327
[TBL] [Abstract][Full Text] [Related]
12. Exosomal glypican-1 discriminates pancreatic ductal adenocarcinoma from chronic pancreatitis.
Moutinho-Ribeiro P; Adem B; Batista I; Silva M; Silva S; Ruivo CF; Morais R; Peixoto A; Coelho R; Costa-Moreira P; Lopes S; Vilas-Boas F; Durães C; Lopes J; Barroca H; Carneiro F; Melo SA; Macedo G
Dig Liver Dis; 2022 Jul; 54(7):871-877. PubMed ID: 34840127
[TBL] [Abstract][Full Text] [Related]
13. Panel of serum miRNAs as potential non-invasive biomarkers for pancreatic ductal adenocarcinoma.
Khan IA; Rashid S; Singh N; Rashid S; Singh V; Gunjan D; Das P; Dash NR; Pandey RM; Chauhan SS; Gupta S; Saraya A
Sci Rep; 2021 Feb; 11(1):2824. PubMed ID: 33531550
[TBL] [Abstract][Full Text] [Related]
14. Noninvasive detection of pancreatic ductal adenocarcinoma using the methylation signature of circulating tumour DNA.
Wu H; Guo S; Liu X; Li Y; Su Z; He Q; Liu X; Zhang Z; Yu L; Shi X; Gao S; Wang H; Pan Y; Ma C; Liu R; Dai M; Jin G; Liang Z
BMC Med; 2022 Nov; 20(1):458. PubMed ID: 36434648
[TBL] [Abstract][Full Text] [Related]
15. Protein biomarkers in pancreatic juice and serum for identification of pancreatic cancer.
Levink IJM; Visser IJ; Koopmann BDM; van Driel LMJW; Poley JW; Cahen DL; Bruno MJ; Fuhler GM
Gastrointest Endosc; 2022 Nov; 96(5):801-813.e2. PubMed ID: 35537661
[TBL] [Abstract][Full Text] [Related]
16. Soluble AXL is a novel blood marker for early detection of pancreatic ductal adenocarcinoma and differential diagnosis from chronic pancreatitis.
Martínez-Bosch N; Cristóbal H; Iglesias M; Gironella M; Barranco L; Visa L; Calafato D; Jiménez-Parrado S; Earl J; Carrato A; Manero-Rupérez N; Moreno M; Morales A; Guerra C; Navarro P; García de Frutos P
EBioMedicine; 2022 Jan; 75():103797. PubMed ID: 34973624
[TBL] [Abstract][Full Text] [Related]
17. Do pancreatic cancer and chronic pancreatitis share the same genetic risk factors? A PANcreatic Disease ReseArch (PANDoRA) consortium investigation.
Campa D; Pastore M; Capurso G; Hackert T; Di Leo M; Izbicki JR; Khaw KT; Gioffreda D; Kupcinskas J; Pasquali C; Macinga P; Kaaks R; Stigliano S; Peeters PH; Key TJ; Talar-Wojnarowska R; Vodicka P; Valente R; Vashist YK; Salvia R; Papaconstantinou I; Shimizu Y; Valsuani C; Zambon CF; Gazouli M; Valantiene I; Niesen W; Mohelnikova-Duchonova B; Hara K; Soucek P; Malecka-Panas E; Bueno-de-Mesquita HBA; Johnson T; Brenner H; Tavano F; Fogar P; Ito H; Sperti C; Butterbach K; Latiano A; Andriulli A; Cavestro GM; Busch ORC; Dijk F; Greenhalf W; Matsuo K; Lombardo C; Strobel O; König AK; Cuk K; Strothmann H; Katzke V; Cantore M; Mambrini A; Oliverius M; Pezzilli R; Landi S; Canzian F
Int J Cancer; 2018 Jan; 142(2):290-296. PubMed ID: 28913878
[TBL] [Abstract][Full Text] [Related]
18. Periostin and CA242 as potential diagnostic serum biomarkers complementing CA19.9 in detecting pancreatic cancer.
Dong D; Jia L; Zhang L; Ma N; Zhang A; Zhou Y; Ren L
Cancer Sci; 2018 Sep; 109(9):2841-2851. PubMed ID: 29945294
[TBL] [Abstract][Full Text] [Related]
19. Inflammatory cytokines and combined biomarker panels in pancreatic ductal adenocarcinoma: Enhancing diagnostic accuracy.
Kruger D; Yako YY; Devar J; Lahoud N; Smith M
PLoS One; 2019; 14(8):e0221169. PubMed ID: 31415645
[TBL] [Abstract][Full Text] [Related]
20. Validation of biomarkers that complement CA19.9 in detecting early pancreatic cancer.
Chan A; Prassas I; Dimitromanolakis A; Brand RE; Serra S; Diamandis EP; Blasutig IM
Clin Cancer Res; 2014 Nov; 20(22):5787-95. PubMed ID: 25239611
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
